Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates

Journal of Applied Toxicology

Volumn 32, Issue 10, 2012, Pages 834-842

  Wen, Dingsheng ^a,b   Liu, Aiming ^c   Chen, Feng ^d   Yang, Julin ^e   Dai, Renke ^a,b  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c NINGBO UNIVERSITY   (China)

^d Guangzhou ImVin Pharmaceutical Co Ltd   (China)

^e Ningbo College of Health Sciences   (China)

Author keywords

Heart toxicity; High throughput; QT prolongation; TdP; Transgenic zebrafish

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; AMITRIPTYLINE; ASTEMIZOLE; ATOMOXETINE; BEPRIDIL; CARVEDILOL; CHLORPROMAZINE; CISAPRIDE; DISOPYRAMIDE; DOMPERIDONE; DOXEPIN; DROPERIDOL; ERYTHROMYCIN; FLECAINIDE; FLUOXETINE; HALOPERIDOL; INDAPAMIDE; KETANSERIN; LEVOFLOXACIN; OFLOXACIN; PAROXETINE; PIMOZIDE; QUINIDINE; ROXITHROMYCIN; SOTALOL; SPARFLOXACIN; TAMOXIFEN; TERFENADINE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CARDIOTOXICITY; CONTROLLED STUDY; HEART EDEMA; HEART MUSCLE; HEART RATE; HISTOLOGY; LARVA; MICROINJECTION; NONHUMAN; PERICARDIUM; PRIORITY JOURNAL; QT PROLONGATION; TRANSGENIC ANIMAL; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARRHYTHMIAS, CARDIAC; BRADYCARDIA; DRUGS, INVESTIGATIONAL; EDEMA; ETHER-A-GO-GO POTASSIUM CHANNELS; GREEN FLUORESCENT PROTEINS; HEART RATE; HEART VENTRICLES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LARVA; MICROINJECTIONS; MICROSCOPY, FLUORESCENCE; MICROSCOPY, VIDEO; PERICARDITIS; PERICARDIUM; POTASSIUM CHANNEL BLOCKERS; RECOMBINANT PROTEINS; ZEBRAFISH;

CANIS FAMILIARIS; DANIO RERIO;

EID: 84865809953     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2755     Document Type: Article

References (38)

1. Burns CG, Milan DJ, Grande EJ, Rottbauer W, MacRae CA, Fishman MC. 2005. High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat. Chem. Biol. 1: 263-264.
2. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. 1993. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc. Res. 27: 2186-2193.
3. Chezalviel F, Weissenburger J, Ertzbischoff O, Poirier JM, Harle X, Davy JM, Biour M, Cheymol G. 1990. Comparison of the cardiac electrophysiological effects of flecainide and hydroquinidine in anesthetized dog: concentration-response relationship. J. Cardiovasc. Pharmacol. 15: 50-56.
4. Crosby HH, Hamlin RL, Strauch SM. 1984. Effects of disopyramide on the electrocardiogram and ventricular function in the unanesthetized dog. J. Vet. Pharmacol. Ther. 7: 167-175.
5. Curigliano G, Cipolla C, de Braud F. 2004. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350: 2618-2621.
6. Di Gioacchino M, Mezzetti A, Mancini M, Guglielmi MD, Lo Medico E, Proietti Franceschilli G, Marzio L, Cuccurullo F. 1987. Study of the cardiovascular effects of clenbuterol in exercise-induced asthma. Respiration 51: 205-213.
7. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, Leaney JL, Witchel HJ, Hancox JC. 2007. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem. Pharmacol. 74: 425-437.
8. Duncan RS, Ridley JM, Dempsey CE, Leishman DJ, Leaney JL, Hancox JC, Witchel HJ. 2006. Erythromycin block of the HERG K+channel: Accessibility to F656 and Y652. Biochem. Biophys. Res. Commun. 341: 500-506.
9. Ficker E, Obejero-Paz CA, Zhao S, Brown AM. 2002. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J. Biol. Chem. 277: 4989-4998.
10. Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. 2004. Torsade de pointes: the clinical considerations. Int. J. Cardiol. 96: 1-6.
11. Heideman W, Antkiewicz DS, Carney SA, Peterson RE. 2005. Zebrafish and cardiac toxicology. Cardiovasc. Toxicol. 5: 203-214.
12. Kagstrom J, Sjogren EL, Ericson AC. 2007. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs. J. Pharmacol. Toxicol. Methods 56: 186-193.
13. Kang JS, Wang L, Chen XL, Triggle DJ, Rampe D. 2001. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+channel HERG. Mol. Pharmacol. 59: 122-126.
14. Karle CA, Kreye VAW, Thomas D, Rockl K, Kathofer S, Zhang W, Kiehn J. 2001. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc. Res. 49: 361-370.
15. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. 2006. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J. Pharmacol. Exp. Ther. 316: 1098-1106.
16. Langheinrich U, Vacun G, Wagner T. 2003. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol. Appl. Pharmacol. 193: 370-382.
17. Milan DJ, Jones IL, Ellinor PT, MacRae CA. 2006. In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. Am. J. Physiol. Heart Circ. Physiol. 291: H269-273.
18. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA. 2003. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 107: 1355-1358.
19. Mittelstadt SW, Hemenway CL, Craig MP, Hove JR. 2008. Evaluation of zebrafish embryos as a model for assessing inhibition of hERG. J. Pharmacol. Toxicol. Methods 57: 100-105.
20. Olsson AG, Ekelund LG, Lang PD, Vollmar J. 1983. Bezafibrate does not influence the QT interval in man. J. Cardiovasc. Pharmacol. 5: 341-342.
21. Paul AA, Witchel HJ, Hancox JC. 2001. Inhibition of HERG potassium channel current by the Class 1a antiarrhythmic agent disopyramide. Biochem. Biophys. Res. Commun. 280: 1243-1250.
22. Paul AA, Witchel HJ, Hancox JC. 2002. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br. J. Pharmacol. 136: 717-729.
23. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad rang of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58: 32-45.
24. Rubart M, Pressler ML, Pride HP, Zipes DP. 1993. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 88: 1832-1844.
25. Sedmera D, Reckova M, deAlmeida A, Sedmerova M, Biermann M, Volejnik J, Sarre A, Raddatz E, McCarthy RA, Gourdie RG, Thompson RP. 2003. Functional and morphological evidence for a ventricular conduction system in zebrafish and Xenopus hearts. Am. J. Physiol. Heart Circ. Physiol. 284: H1152-1160.
26. Stork D, Timin EN, Berjukow S, Huber C, Hohaus A, Auer M, Hering S. 2007. State dependent dissociation of HERG channel inhibitors. Br. J. Pharmacol. 151: 1368-1376.
27. Tang Q, Li ZQ, Li W, Guo J, Sun HY, Zhang XH, Lau CP, Tse HF, Zhang S, Li GR. 2008. The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-a-go-go-related gene (hERG) potassium channels. Br. J. Pharmacol. 155: 365-373.
28. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ. 1999. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br. J. Pharmacol. 128: 479-485.
29. Thisse C, Zon LI. 2002. Organogenesis--heart and blood formation from the zebrafish point of view. Science 295: 457-462.
30. Thomas D, Gut B, Karsai S, Wimmer AB, Wu K, Wendt-Nordahl G, Zhang W, Kathofer S, Schoels W, Katus HA, Kiehn J, Karle CA. 2003. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn Schmiedebergs Arch. Pharmacol. 368: 41-48.
31. Toyoshima S, Kanno A, Kitayama T, Sekiya K, Nakai K, Haruna M, Mino T, Miyazaki H, Yano K, Yamamoto K. 2005. QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J. Pharmacol. Sciences 99: 459-471.
32. Volberg WA, Koci BJ, Su WG, Lin J, Zhou J. 2002. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302: 320-327.
33. Vormberge T, Hoffmann M, Himmel H. 2006. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. J. Pharmacol. Toxicol. Methods 54: 130-140.
34. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B. 2005. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J. Card. Fail. 11: 684-690.
35. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. 2002. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. 512: 59-66.
36. Yan GX, Shimizu W, Antzelevitch C. 1998. Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation 98: 1921-1927.
37. Yao X, Anderson DL, Ross SA, Lang DG, Desai BZ, Cooper DC, Wheelan P, McIntyre MS, Bergquist ML, MacKenzie KI, Becherer JD, Hashim MA. 2008. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154: 1446-1456.
38. Zhao XY, Li GY, Liu Y, Chai LM, Chen JX, Zhang Y, Du ZM, Lu YJ, Yang BF. 2008. Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. Br. J. Pharmacol. 154: 105-113.